3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
2
Phase 2
1
Status
Recruiting
3
Completed
2
Sponsor Class
INDUSTRY
2
Study Type
Interventional
2
Sponsor
Conditions
Myasthenia Gravis
2
Interventions
Cyclophosphamide
299
Cisplatin
298
Paclitaxel
257
Radiotherapy
255
Fluorouracil
234
Carboplatin
234
Docetaxel
230
Doxorubicin
216
Dexamethasone
166
Gemcitabine
156
Vincristine
147
Etoposide
136
Leucovorin
133
Capecitabine
129
Bevacizumab
129
Prednisone
125
Rituximab
118
Methotrexate
118
Cytarabine
110
Filgrastim
99
Trastuzumab
97
Oxaliplatin
96
pembrolizumab
83
Pemetrexed
73
Epirubicin
70
Tamoxifen
69
Drug Therapy
69
Irinotecan
65
Granulocyte Colony-Stimulating Factor
60
Daunorubicin
58
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Phase 3
×
Completed
×
efgartigimod alfa
×
Clear all
NCT03770403
2023-07-14
ADAPT+
argenx
Phase 3
Completed
151 enrolled
11 charts
NCT03669588
2022-02-08
ADAPT
argenx
Phase 3
Completed
167 enrolled
18 charts